• Je něco špatně v tomto záznamu ?

The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies

CK. Cheung, J. Barratt, A. Liew, H. Zhang, V. Tesar, R. Lafayette

. 2023 ; 3 (-) : 1346769. [pub] 20240201

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24005895

Immunoglobulin A nephropathy (IgAN), characterized by mesangial deposition of galactose-deficient-IgA1 (Gd-IgA1), is the most common biopsy-proven primary glomerulonephritis worldwide. Recently, an improved understanding of its underlying pathogenesis and the substantial risk of progression to kidney failure has emerged. The "four-hit hypothesis" of IgAN pathogenesis outlines a process that begins with elevated circulating levels of Gd-IgA1 that trigger autoantibody production. This results in the formation and deposition of immune complexes in the mesangium, leading to inflammation and kidney injury. Key mediators of the production of Gd-IgA1 and its corresponding autoantibodies are B-cell activating factor (BAFF), and A proliferation-inducing ligand (APRIL), each playing essential roles in the survival and maintenance of B cells and humoral immunity. Elevated serum levels of both BAFF and APRIL are observed in patients with IgAN and correlate with disease severity. This review explores the complex pathogenesis of IgAN, highlighting the pivotal roles of BAFF and APRIL in the interplay between mucosal hyper-responsiveness, B-cell activation, and the consequent overproduction of Gd-IgA1 and its autoantibodies that are key features in this disease. Finally, the potential therapeutic benefits of inhibiting BAFF and APRIL in IgAN, and a summary of recent clinical trial data, will be discussed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005895
003      
CZ-PrNML
005      
20240412130851.0
007      
ta
008      
240405e20240201sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fneph.2023.1346769 $2 doi
035    __
$a (PubMed)38362118
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Cheung, Chee Kay $u Division of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom $u John Walls Renal Unit, University Hospitals of Leicester National Health Service (NHS) Trust, Leicester, United Kingdom
245    14
$a The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies / $c CK. Cheung, J. Barratt, A. Liew, H. Zhang, V. Tesar, R. Lafayette
520    9_
$a Immunoglobulin A nephropathy (IgAN), characterized by mesangial deposition of galactose-deficient-IgA1 (Gd-IgA1), is the most common biopsy-proven primary glomerulonephritis worldwide. Recently, an improved understanding of its underlying pathogenesis and the substantial risk of progression to kidney failure has emerged. The "four-hit hypothesis" of IgAN pathogenesis outlines a process that begins with elevated circulating levels of Gd-IgA1 that trigger autoantibody production. This results in the formation and deposition of immune complexes in the mesangium, leading to inflammation and kidney injury. Key mediators of the production of Gd-IgA1 and its corresponding autoantibodies are B-cell activating factor (BAFF), and A proliferation-inducing ligand (APRIL), each playing essential roles in the survival and maintenance of B cells and humoral immunity. Elevated serum levels of both BAFF and APRIL are observed in patients with IgAN and correlate with disease severity. This review explores the complex pathogenesis of IgAN, highlighting the pivotal roles of BAFF and APRIL in the interplay between mucosal hyper-responsiveness, B-cell activation, and the consequent overproduction of Gd-IgA1 and its autoantibodies that are key features in this disease. Finally, the potential therapeutic benefits of inhibiting BAFF and APRIL in IgAN, and a summary of recent clinical trial data, will be discussed.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Barratt, Jonathan $u Division of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom $u John Walls Renal Unit, University Hospitals of Leicester National Health Service (NHS) Trust, Leicester, United Kingdom
700    1_
$a Liew, Adrian $u The Kidney & Transplant Practice, Mount Elizabeth Novena Hospital, Singapore
700    1_
$a Zhang, Hong $u Renal Division in the Department of Medicine, Peking University First Hospital, Beijing, China
700    1_
$a Tesar, Vladimir $u Department of Nephrology, First School of Medicine and General University Hospital, Charles University, Prague, Czechia
700    1_
$a Lafayette, Richard $u Department of Medicine, Stanford University, Stanford, CA, United States
773    0_
$w MED00214681 $t Frontiers in nephrology $x 2813-0626 $g Roč. 3 (20240201), s. 1346769
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38362118 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412130843 $b ABA008
999    __
$a ok $b bmc $g 2076059 $s 1215657
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 3 $c - $d 1346769 $e 20240201 $i 2813-0626 $m Frontiers in nephrology $n Front Nephrol $x MED00214681
LZP    __
$a Pubmed-20240405
Zpět

Najít záznam

Citační ukazatele

    Možnosti archivace